PSivida CEO To Discuss Sustained Delivery Of Antibodies In Ophthalmology And Systemic Disease At International Symposium On Integrated Functionalities
pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is
a leader in developing sustained release drugs for treatment of
back-of-the-eye diseases, has announced that pSivida President and Chief
pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, has announced that pSivida President and Chief Executive Officer, Paul Ashton, Ph.D., will speak today at the International Symposium on Integrated Functionalities 2013 meeting at the Hilton DFW Lakes Executive Conference Center in Grapevine, Texas. Dr. Ashton’s talk, “Materials Science to Bridge Biologic Breakthrough to Therapeutic Breakthrough,” will focus on pSivida’s Tethadur™ platform and sustained delivery of antibodies in ophthalmology and systemic disease. Tethadur is an application of pSivida’s BioSilicon™ technology platform designed to provide sustained delivery of large biologic molecules, including proteins, antibodies and peptides. BioSilicon utilizes an injectable, bioerodible, nanostructured, porous BioSilicon material for drug delivery. The sizes of the pores in the BioSilicon material are manufactured using nanotechnology to accommodate specific protein, peptide or antibody molecules that are then released at a controlled, sustained rate. The technology also has significant potential for use in many applications. The symposium brings together leaders in fundamental and applied science in materials integration, design and fabrication. The meeting has been sponsored by the Materials Research Society since 1987. About pSivida pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. pSivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert™ and BioSilicon™. The injectable, sustained release micro-insert ILUVIEN® for the treatment of chronic DME considered insufficiently responsive to available therapies, licensed to Alimera Sciences, Inc., has received marketing authorization in Austria, France, Germany, Portugal, Spain and the U.K. and is awaiting authorization in Italy. Alimera has resubmitted the New Drug Application for ILUVIEN for DME to the U.S. Food and Drug Administration. pSivida plans to institute pivotal Phase III clinical trials for the treatment of posterior uveitis, a chronic back-of-the-eye disease, with the same micro-insert as ILUVIEN for DME. An investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. pSivida's FDA-approved Retisert® licensed to Bausch & Lomb Incorporated provides long-term, sustained drug delivery to treat posterior uveitis.